Holen Sie sich die Stockscreener-App
1.38
0.72%
-0.01
Handel nachbörslich:
1.40
0.02
+1.45%
Schlusskurs vom Vortag:
$1.39
Offen:
$1.4
24-Stunden-Volumen:
207.10K
Relative Volume:
0.42
Marktkapitalisierung:
$45.30M
Einnahmen:
$3.04M
Nettoeinkommen (Verlust:
$-33.97M
KGV:
-1.0376
EPS:
-1.33
Netto-Cashflow:
$-52.47M
1W Leistung:
-6.76%
1M Leistung:
-6.76%
6M Leistung:
-51.24%
1J Leistung:
-60.00%
1-Tages-Spanne:
$1.35
$1.41
1-Wochen-Bereich:
$1.35
$1.52
52-Wochen-Spanne:
$1.24
$8.75
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Firmenname
Rani Therapeutics Holdings Inc
Sektor
Branche
Telefon
(408) 457-3700
Adresse
2051 RINGWOOD AVENUE, SAN JOSE
Vergleichen Sie RANI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
1.38 | 45.30M | 3.04M | -33.97M | -52.47M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-02 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-14 | Eingeleitet | Maxim Group | Buy |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-07-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Rani Therapeutics Holdings Inc Aktie (RANI) Neueste Nachrichten
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Consensus PT from Brokerages - MarketBeat
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Consensus Target Price from Analysts - Defense World
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Average Target Price from Brokerages - MarketBeat
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Shares Purchased by Geode Capital Management LLC - Defense World
Rani Therapeutics stock hits 52-week low at $1.29 - Investing.com India
Rani Therapeutics stock hits 52-week low at $1.29 By Investing.com - Investing.com South Africa
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Shares Acquired by Stifel Financial Corp - Defense World
Analysts Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Target Price at $11.71 - Defense World
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Average PT from Brokerages - MarketBeat
Rani Therapeutics stock hits 52-week low at $1.32 - Investing.com
Insider Buying: Kate Mckinley Acquires Shares in Rani Therapeuti - GuruFocus.com
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Insider Kate Mckinley Acquires 17,960 Shares - MarketBeat
Rani Therapeutics stock hits 52-week low at $1.85 By Investing.com - Investing.com Nigeria
Rani Therapeutics stock hits 52-week low at $1.85 - Investing.com India
CEO Talat Imran Acquires Additional Shares of Rani Therapeutics Holdings Inc (RANI) - GuruFocus.com
Rani Therapeutics stock hits 52-week low at $1.94 By Investing.com - Investing.com Nigeria
Rani Therapeutics stock hits 52-week low at $1.94 - Investing.com India
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Average Target Price from Analysts - Defense World
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Price Target at $11.71 - MarketBeat
What is Zacks Small Cap’s Forecast for RANI FY2024 Earnings? - Defense World
What is Zacks Small Cap's Forecast for RANI FY2024 Earnings? - MarketBeat
RANI: Third Quarter Update - MSN
Rani Therapeutics' (RANI) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Rani Therapeutics Advances in Biotherapeutics Market - TipRanks
Rani Therapeutics Holdings Inc (RANI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in Rani Therapeutics H - GuruFocus.com
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update - The Manila Times
Rani Therapeutics Slashes Q3 Loss by 31%, Secures $20M Funding for GLP-1 Development | RANI Stock News - StockTitan
Rani Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) PT at $11.71 - Defense World
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Sees Significant Growth in Short Interest - MarketBeat
Allied Gaming & Entertainment And 2 Other US Penny Stocks To Watch - Simply Wall St
RANI: New Triagonist Data in Weight Loss - Zacks Small Cap Research
Rani Therapeutics shares hold buy rating on positive preclinical data By Investing.com - Investing.com Australia
Rani Therapeutics stock gets positive outlook from H.C. Wainwright after novel obesity candidate progress - Investing.com Australia
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.75% - MSN
Rani Therapeutics shares hold buy rating on positive preclinical data - Investing.com
Rani Therapeutics (NASDAQ:RANI) Receives "Buy" Rating from HC Wainwright - MarketBeat
Finanzdaten der Rani Therapeutics Holdings Inc-Aktie (RANI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rani Therapeutics Holdings Inc-Aktie (RANI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Imran Talat | Chief Executive Officer |
Dec 09 '24 |
Buy |
1.94 |
10,296 |
19,974 |
494,751 |
| South Cone Investments Limited | 10% Owner |
Oct 15 '24 |
Sale |
2.65 |
3,829,360 |
10,141,674 |
8,302,194 |
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):